TBPH · Insider Trading
Theravance Biopharma, Inc.
Every open-market purchase and sale reported by TBPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Andrew M Weiss | — | J | −22,371,180 | −$380.31M |
| 2026-09-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | D | −189,826 | — |
| 2026-09-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | D | −213,476 | — |
| 2026-09-24 | Donal O'Connor | Director | D | −80,213 | — |
| 2026-09-24 | Deepika Pakianathan | Director | D | −64,074 | — |
| 2026-09-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | D | −1,726,989 | — |
| 2026-09-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | D | −336,841 | — |
| 2026-09-24 | Susannah Gray | Director | D | −48,146 | — |
| 2026-09-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | D | −355,168 | — |
| 2026-09-24 | Alsup Laurie Smaldone | Director | D | −80,989 | — |
| 2026-09-24 | Dean J Mitchell | Director | D | −97,213 | — |
| 2026-09-17 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | −13,314 | −$226.79K |
| 2026-08-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | −8,112 | −$137.50K |
| 2026-08-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | −6,258 | −$106.07K |
| 2026-08-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | −5,667 | −$96.06K |
| 2026-08-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | −20,034 | −$339.58K |
| 2026-08-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | −7,952 | −$134.79K |
| 2026-07-08 | Eli Samaha | 10%+ Owner | Sell | −6,964 | −$119.40K |
| 2026-07-01 | Eli Samaha | 10%+ Owner | Sell | −336,697 | −$5.79M |
| 2026-06-23 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | A | +18,750 | — |
| 2026-06-17 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | −13,314 | −$218.17K |
| 2026-06-16 | Susannah Gray | Director | A | +6,009 | — |
| 2026-06-16 | Deepika Pakianathan | Director | A | +6,009 | — |
| 2026-06-16 | Alsup Laurie Smaldone | Director | A | +6,009 | — |
| 2026-06-16 | Dean J Mitchell | Director | A | +6,009 | — |
| 2026-06-16 | Donal O'Connor | Director | A | +6,009 | — |
| 2026-05-22 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | −8,829 | −$146.12K |
| 2026-05-22 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | −20,038 | −$331.63K |
| 2026-05-22 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | −8,670 | −$143.49K |
| 2026-05-22 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | −5,678 | −$93.97K |
| 2026-05-22 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | −6,827 | −$112.99K |
| 2026-04-03 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | A | +37,500 | — |
| 2026-04-03 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | A | +18,750 | — |
| 2026-04-03 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | A | +37,500 | — |
| 2026-04-03 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | A | +75,000 | — |
| 2026-03-18 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | −31,067 | −$433.64K |
| 2026-02-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | −13,929 | −$273.84K |
| 2026-02-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | −16,851 | −$331.29K |
| 2026-02-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | −20,672 | −$406.41K |
| 2026-02-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | −20,833 | −$409.58K |
| 2026-02-24 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | F | −74,975 | −$1.47M |
| 2025-12-05 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | Sell | −31,067 | −$582.50K |
| 2025-12-01 | Eran Broshy | Director | Sell | −29,501 | −$590.02K |
| 2025-11-24 | Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | F | −9,060 | −$162.17K |
| 2025-11-24 | Aziz Sawaf | SVP & CHIEF FINANCIAL OFFICER | F | −18,627 | −$333.42K |
| 2025-11-24 | Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | F | −19,024 | −$340.53K |
| 2025-11-24 | Aine Miller | SVP, DEV & HEAD OF IRE OFFICE | F | −6,989 | −$125.10K |
| 2025-11-21 | Rick E Winningham | CHIEF EXECUTIVE OFFICER | MIXED | −56,817 | −$1.02M |
| 2025-11-14 | Eran Broshy | Director | Sell | −45,000 | −$809.25K |
| 2025-11-13 | Eran Broshy | Director | Sell | −59,000 | −$1.07M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Eli Samaha | 10%+ Owner | 9,167,489 | $156.12M |
| Rhonda Farnum | SVP, COMM & MEDICAL AFFAIRS | 89,062 | $1.52M |
| Rick E Winningham | CHIEF EXECUTIVE OFFICER | 76,875 | $1.31M |
| Eran Broshy | Director | 60,204 | $1.03M |
| Jeremy T Grant | Director | 32,954 | $561.21K |
| Brett A. Grimaud | SVP, GEN COUNSEL AND SECRETARY | 23,439 | $399.17K |
| Dean J Mitchell | Director | 6,009 | $102.33K |
| Deepika Pakianathan | Director | 6,009 | $102.33K |
| Susannah Gray | Director | 6,009 | $102.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TBPH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.